No Improvement in OS With Atezolizumab in Relapsing TNBC : c

Early relapsing disease has again shown the limitations of immunotherapy in triple-negative breast cancer after a trial found no overall survival benefit with the drug.

Related Keywords

Boston , Massachusetts , United States , Singapore , Dana Farber Cancer Institute , Saram Tolaney , , Susanf Smith Center , Division Of Breast Oncology , European Society For Medical Oncology , National Cancer Center Singapore , Breast Cancer Annual Congress , European Society , Medical Oncology , Breast Oncology , Medscape Medical ,